Chatbot for Hereditary Cancer Syndromes

Phase-Based Progress Estimates
Hereditary Cancer Syndromes+2 More
Chatbot - Other
All Sexes
What conditions do you have?

Study Summary

This trial will compare a mobile health platform that uses artificial intelligence and natural language processing (a 'chatbot') to usual care in order to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of familial cancer syndrome in an all-Medicaid gynecology clinic.

Eligible Conditions
  • Hereditary Cancer Syndromes
  • Gynecologic Cancers

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 2 years

2 years
Genetic screening method
Facilitator of inequity in the utilization of genetic services
Genetic screening method
Genetic screening method

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Usual Care
1 of 2
1 of 2

Active Control

Experimental Treatment

150 Total Participants · 2 Treatment Groups

Primary Treatment: Chatbot · No Placebo Group · N/A

Experimental Group · 1 Intervention: Chatbot · Intervention Types: Other
Usual CareNoIntervention Group · 1 Intervention: Usual Care · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
983 Previous Clinical Trials
1,338,302 Total Patients Enrolled
Melissa K Frey, MDPrincipal InvestigatorWeill Medical College of Cornell University

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a high risk of cervical cancer if you are younger than 8 years old.
You are scheduled for a new patient appointment in the gynecology clinic
You have not had prior genetic testing for hereditary cancer syndromes.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 10th, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.